NF1 and neoplasm: Although ARAF mutations were not observed in the tumor cell lines in our study, either ARAF heterodimerization or the emergence of ARAF mutations may drive resistance to type II RAF inhibitors, such as tovorafenib in NF1-LOF mutant or RAS-mutant tumors.